Antibody molecules for cancer treatment
US11028169B2 · kind B2 · utility
1Cited by
2References
67Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2017 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | May 18, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.